Get the Stockscreener App
196.91
0.20%
0.39
After Hours:
196.91
Krystal Biotech Inc stock is traded at $196.91, with a volume of 138.22K.
It is up +0.20% in the last 24 hours and up +12.19% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$196.52
Open:
$197.05
24h Volume:
138.22K
Relative Volume:
0.63
Market Cap:
$5.71B
Revenue:
$241.52M
Net Income/Loss:
$52.37M
P/E Ratio:
-133.95
EPS:
-1.47
Net Cash Flow:
$58.06M
1W Performance:
+10.56%
1M Performance:
+12.19%
6M Performance:
+20.93%
1Y Performance:
+95.62%
1-Day Range:
$194.80
$198.87
1-Week Range:
$175.09
$198.87
52-Week Range:
$99.00
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
196.91 | 5.71B | 241.52M | 52.37M | 58.06M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech to Present at Upcoming Investor Conferences - The Manila Times
Krystal Biotech CEO to Present at Citi and Evercore Healthcare Conferences | KRYS Stock News - StockTitan
Intech Investment Management LLC Purchases Shares of 7,270 Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Swiss National Bank Grows Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Summit Trail Advisors LLC Invests $1.89 Million in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Eagle Asset Management Inc. Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
(KRYS) Proactive Strategies - Stock Traders Daily
Jennison Associates LLC Sells 110,333 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Segall Bryant & Hamill LLC Buys 122,407 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
First Turn Management LLC Sells 41,280 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Victory Capital Management Inc. Has $17.89 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Redmile Group, LLC Adjusts Stake in Krystal Biotech Inc - GuruFocus.com
Principal Financial Group Inc. Sells 3,743 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
FMR LLC's Strategic Acquisition of Krystal Biotech Inc Shares - GuruFocus.com
High Growth Tech Stocks Featuring Three Prominent US Companies - Simply Wall St
Krystal Biotech Inc (KRYS) Quarterly 10-Q Report - Quartzy
Krystal Biotech to Present at Stifel 2024 Healthcare Conference - StockTitan
Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Raised by TimesSquare Capital Management LLC - MarketBeat
Janney Montgomery Scott LLC Buys 5,415 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Chardan Capital Predicts Lower Earnings for Krystal Biotech - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Simply Wall St
Q2 EPS Estimates for Krystal Biotech Raised by William Blair - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
HC Wainwright Predicts Reduced Earnings for Krystal Biotech - MarketBeat
HC Wainwright Forecasts Higher Earnings for Krystal Biotech - MarketBeat
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference - StockTitan
Krystal Biotech FY2024 EPS Forecast Raised by William Blair - MarketBeat
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction - MSN
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $206.00 at Citigroup - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Posts Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript - Insider Monkey
Krystal Biotech Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Krystal stock gains modest boost from Citi, but compliance risks linger - Investing.com Canada
Krystal Biotech Inc (KRYS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates - MSN
Krystal Biotech Inc (KRYS) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Krystal Biotech Inc (KRYS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Krystal Biotech Faces Challenges in Scaling VYJUVEK Production Amid Regulatory Hurdles - TipRanks
Earnings call: Krystal Biotech reports robust Q3 2024 results By Investing.com - Investing.com Nigeria
Krystal Biotech Reports Strong Q3 2024 Performance - TipRanks
Earnings call: Krystal Biotech reports robust Q3 2024 results - Investing.com India
Krystal Biotech (NASDAQ:KRYS) Shares Gap DownHere's Why - MarketBeat
Krystal Biotech earnings missed by $0.08, revenue topped estimates - Investing.com UK
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Krystal Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Are Options Traders Betting on a Big Move in Krystal Biotech (KRYS) Stock? - MSN
Where are the Opportunities in (KRYS) - Stock Traders Daily
Earnings To Watch: Krystal Biotech Inc (KRYS) Reports Q3 2024 Re - GuruFocus.com
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):